Presumably emerging at the end of 2019, the COVID-19 pandemic has posed a severe threat to public health and safety, inducing much stress on daily living and working. Countries around the world have been actively engaged in the development and inoculation of COVID-19 vaccines. It is widely acknowledged that the first-generation SARS-CoV-2 vaccines have played a significant role in controlling the COVID-19 pandemic, preventing severe disease picture and reducing mortality. However, while the entire world is working to combat COVID-19, the virus itself is constantly changing.
The continuous emergence of SARS-CoV-2 variants, as well as ongoing breakthrough infections, have brought additional challenges for the next phase. Meanwhile, it is a commonly accepted fact that the neutralizing antibody level in the recipients decreases with time, and the vaccine’s protective efficacy is gradually weakened. There is a heated debate about whether to carry out the booster vaccination strategy. The team of researchers from the Children’s Hospital Zhejiang University School of Medicine paid close attention to the COVID-19 situation and has attempted to contribute to resolving some of the controversies surrounding COVID-19 by summarizing and analyzing the necessity of booster vaccination, priority groups for booster vaccination, heterologous booster vaccination strategies and safety considerations of a booster vaccination.
They came to the conclusion that it is essential to implement booster immunization strategies. Priority should be given to high-risk groups, the elderly and immunocompromised people. In addition, heterologous vaccination, which involves the administration of a different vaccine than previously administered, has longer persistence and a broader spectrum than receiving the same vaccine, making it better suited to dealing with SARS-CoV-2 variants.
Reference: Meng H, Mao J, Ye Q. Strategies and safety considerations of booster vaccination in COVID-19. Bosn J of Basic Med Sci [Internet]. 2022Apr.3 [cited 2022Apr.10];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7082
Editor: Merima Bukva, MPharm
Leave a Reply